These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35331126)

  • 1. Mini Review on Cariprazine: A Promising Antipsychotic Agent.
    Patel A; Patel A; Patel D; Patel K; Bambharoliya T
    CNS Neurol Disord Drug Targets; 2023; 22(2):226-236. PubMed ID: 35331126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
    Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
    [No Abstract]   [Full Text] [Related]  

  • 4. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Cariprazine and its Major Metabolites.
    Periclou A; Phillips L; Ghahramani P; Kapás M; Carrothers T; Khariton T
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):53-69. PubMed ID: 33141308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dopamine D
    Calabrese F; Tarazi FI; Racagni G; Riva MA
    CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study.
    Yeung PP; Johnson KA; Riesenberg R; Orejudos A; Riccobene T; Kalluri HV; Malik PR; Varughese S; Findling RL
    J Child Adolesc Psychopharmacol; 2023 Aug; 33(6):232-242. PubMed ID: 37437109
    [No Abstract]   [Full Text] [Related]  

  • 8. Cariprazine:New dopamine biased agonist for neuropsychiatric disorders.
    De Deurwaerdère P
    Drugs Today (Barc); 2016 Feb; 52(2):97-110. PubMed ID: 27092339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Dopamine D
    Huang M; He W; Kiss B; Farkas B; Adham N; Meltzer HY
    J Pharmacol Exp Ther; 2019 Nov; 371(2):517-525. PubMed ID: 31511365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
    Laszlovszky I; Barabássy Á; Németh G
    Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The preclinical discovery and development of cariprazine for the treatment of schizophrenia.
    Wesołowska A; Partyka A; Jastrzębska-Więsek M; Kołaczkowski M
    Expert Opin Drug Discov; 2018 Aug; 13(8):779-790. PubMed ID: 29722587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine in Bipolar Depression and Mania: State of the Art.
    Mazza M; Marano G; Traversi G; Carocci V; Romano B; Janiri L
    CNS Neurol Disord Drug Targets; 2018; 17(10):723-727. PubMed ID: 30152291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine: First Global Approval.
    McCormack PL
    Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.
    Citrome L
    Neuropsychiatr Dis Treat; 2018; 14():2563-2577. PubMed ID: 30323605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine.
    Choi YK; Adham N; Kiss B; Gyertyán I; Tarazi FI
    CNS Spectr; 2017 Dec; 22(6):484-494. PubMed ID: 28059046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis.
    Durgam S; Earley W; Lu K; Németh G; Laszlovszky I; Volk S; Litman RE
    Int J Clin Pract; 2017 Dec; 71(12):. PubMed ID: 29119668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.